CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Fundação Pio XII (FP). Hospital do Câncer de Barretos (Institutional affiliation from the last research proposal) Birthplace: França
Graduated in Applied Biology from the University of Minho, Portugal (2005), PhD in Health Sciences from the University of Minho (2010) and Post-Doctorate (until January 2013) at the same institution. Currently, she holds the positions of Dean for Academic Affairs and Professor of Cellular and Molecular Biology in the Medicine course at the Barretos School of Health Sciences Dr. Paulo Prata. She is a Researcher at the Barretos Cancer Hospital, Pio XII Foundation, where she is a permanent professor of the Postgraduate Course in Oncology and a member of the Postgraduate Council. She has been a CNPq Level 2 Research Productivity Scholar since 2017. Her field of expertise is Molecular and Cellular Biology and her research area is Oncobiology, being the leader of the research group on Microenvironment and Tumor Metabolism at the Molecular Oncology Research Center, Barretos Cancer Hospital. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Renal Carcinoma is an aggressive cancer and is usually diagnosed in later stages. Clear cell Renal Cell Carcinoma (ccRCC) is the most common subtype of Renal Carcinoma, accounting for about 70% of cases. The ccRCC is mainly characterized by mutation in VHL, a gene that plays an important role in the reprogramming of energy metabolism, among others, by modulating the expression of HIF-1A a…
In the context of metabolic reprogramming of tumor cells (Warburg effect), several proteins show an increased expression, including monocarboxylate transporters (MCTs). Recently, MCT1 was identified as a major determinant of the sensitivity to 3-bromopyruvate (3-BP), one of the most promising inhibitors of glycolytic metabolism. So, in addition to a potential therapeutic target, MCT1 aris…
Introduction: Penile cancer is a rare neoplasm with high incidence in Brazil. It affects men with a low level of education, and is associated with poor hygiene habits and sexually transmitted infections. The disease carries a great stigma, which delays diagnosis and restricts treatment in most cases. From the metabolic point of view, it is known that the reprogramming of glucose metabolis…
Clear-cell renal cell carcinoma (ccRCC), the most lethal type of neoplasia among the urologic malignancies, accounts for 75-85% of all kidney cancers. In clinical practice, even in the era of immunotherapy, sunitinib is often used as the first line of treatment against this neoplasia. However, despite presenting an initial response, about 70% of patients treated with this drug develop res…
Different tumor cells present a metabolic reprogramming characterized by the switch of the main energy pathway (oxidative phosphorylation) to glycolysis, even in the presence of sufficient oxygen, denominated the Warburg effect. Pyruvate dehydrogenase kinase (PDK) plays a role in this metabolic reprogramming, due to its inhibitory action on the pyruvate dehydrogenase complex, diverting th…
Currently, lymphomas constitute approximately 3% of neoplasms worldwide and are characterized by the abnormal growth of B and T lymphocytes or natural killer (NK) cells. Among aggressive B-cell lymphomas, large B-cell lymphoma (DLBCL) is one of the most biologically and genetically distinct subtypes and, thus, presents heterogeneity in response to standard treatment, which consists of che…
(Only some records are available in English at this moment)
Introduction: Clear cell renal cell carcinoma (ccRCC) accounts for 75-85% of renal malignancies, being the most lethal subtype of urological cancers. Despite the presence of immunotherapy in clinical practice, sunitinib is frequently used for the treatment of ccRCC, and is even adopted by the Brazilian public health system (SUS) for metastatic cases. However, approximately 70% of patients…
| 1 / 1 | Ongoing grants |
| 3 / 1 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 12 / 12 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 18 / 16 | All research grants and scholarships |
| Associated processes | |